Waregem (Belgium) / Rotterdam (Netherlands)*, 10 May 2010 – The Annual General Meeting of Shareholders held today has approved all motions put forward by the Board of Directors of Arseus.
The shareholders adopted, amongst other things, the annual accounts 2009 and determined the dividend over 2009 at € 0.36 per share. The shareholders granted full discharge to the directors and the statutory auditor who were active during the financial year 2009. Messrs Peek (chairman), Stols and Vandewalle were reappointed as independent director for a period of 4 years. PricewaterhouseCoopers Bedrijfsrevisoren bcvba was reappointed as statutory auditor for the financial years 2010 through 2012.
The gross dividend paid out by Arseus (coupon number 3) will amount to € 0.36 per share. The net dividend will amount to € 0.27 per share, being gross dividend less 25% Belgian dividend withholding tax. Any shares accompanied by a VVPR-strip (coupon number 3) will be subject to a Belgian withholding tax of only 15%, so a net dividend of € 0.306 per share will be paid on those shares.
The timetable is as follows:
12 May Ex-dividend quotation
14 May Record date
17 May Dividend payable
For more information:
Constantijn van Rietschoten, Director Corporate Communications
+31 88 33 11 222 (Office)
+31 6 536 91 585 (Mobile)
constantijn.van.rietschoten@arseus.com
Arseus profile
Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the European healthcare sector. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical IT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
* This press release was sent out by Arseus NV and Arseus BV.
Please open the link below for the press release: